Involvement of the kynurenine pathway in the pathogenesis of Parkinson’s disease

Adams, 2012, The kynurenine pathway in brain tumor pathogenesis, Cancer Res., 72, 5649, 10.1158/0008-5472.CAN-12-0549 Adams, 2014, Involvement of the kynurenine pathway in human glioma pathophysiology, PLoS One, 9, e112945, 10.1371/journal.pone.0112945 Aguilera, 2007, Time-related changes in constitutive and inducible nitric oxide synthases in the rat striatum in a model of Huntington's disease, Neurotoxicology, 28, 1200, 10.1016/j.neuro.2007.07.010 Alberio, 2012, Discovery and verification of panels of T-lymphocyte proteins as biomarkers of Parkinson's disease, Scientific Rep., 2, 953, 10.1038/srep00953 Allen Reish, 2015, Role of alpha-synuclein in inducing innate and adaptive immunity in Parkinson disease, J. Parkinson's Disease, 5, 1, 10.3233/JPD-140491 Amaral, 2013, Structural basis of kynurenine 3-monooxygenase inhibition, Nature, 496, 382, 10.1038/nature12039 Anderson, 2014, Local melatonin regulates inflammation resolution: a common factor in neurodegenerative: psychiatric and systemic inflammatory disorders, CNS & neurological disorders drug targets, 13, 817, 10.2174/1871527313666140711091400 Anderson, 2014, Neurodegeneration in Parkinson's disease: interactions of oxidative stress: tryptophan catabolites and depression with mitochondria and sirtuins, Mol. Neurobiol., 49, 771, 10.1007/s12035-013-8554-z Anderson, 2014, TRYCAT pathways link peripheral inflammation nicotine somatization and depression in the etiology and course of parkinson's disease, CNS Neurol. Disord. Drug Targets, 13, 137, 10.2174/18715273113129990082 Annese, 2015, Metalloproteinase-9 contributes to inflammatory glia activation and nigro-striatal pathway degeneration in both mouse and monkey models of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced Parkinsonism, Brain Struct. Funct., 220, 703, 10.1007/s00429-014-0718-8 Baltazar, 2014, Pesticides exposure as etiological factors of Parkinson's disease and other neurodegenerative diseases–a mechanistic approach, Toxicol. Lett., 230, 85, 10.1016/j.toxlet.2014.01.039 Barcia, 2004, Evidence of active microglia in substantia nigra pars compacta of parkinsonian monkeys 1 year after MPTP exposure, Glia, 46, 402, 10.1002/glia.20015 Barcia, 2011, IFN-gamma signaling, with the synergistic contribution of TNF-alpha, mediates cell specific microglial and astroglial activation in experimental models of Parkinson's disease, Cell Death Dis., 2, e142, 10.1038/cddis.2011.17 Barcia, 2012, ROCK/Cdc42-mediated microglial motility and gliapse formation lead to phagocytosis of degenerating dopaminergic neurons in vivo, Sci. Rep., 2, 809, 10.1038/srep00809 Barcia, 2012, IFN-gamma signaling, with the synergistic contribution of TNF-alpha, mediates cell specific microglial and astroglial activation in experimental models of Parkinson's disease, Cell Death Dis., 3, e379, 10.1038/cddis.2012.123 Barcia, 2013, Persistent phagocytic characteristics of microglia in the substantia nigra of long-term Parkinsonian macaques, J. Neuroimmunol., 261, 60, 10.1016/j.jneuroim.2013.05.001 Barth, 2009, Kynurenic acid triggers firm arrest of leukocytes to vascular endothelium under flow conditions, J. Biol. Chem., 248, 19189, 10.1074/jbc.M109.024042 Bay-Richter, 2014, A role for inflammatory metabolites as modulators of the glutamate N-methyl-d-aspartate receptor in depression and suicidality, Brain Behav. Immun. Bay-Richter, 2015, A role for inflammatory metabolites as modulators of the glutamate N-methyl-d-aspartate receptor in depression and suicidality, Brain Behav. Immun., 43, 110, 10.1016/j.bbi.2014.07.012 Beal, 1986, Replication of the neurochemical characteristics of Huntington's disease by quinolinic acid, Nature, 321, 168, 10.1038/321168a0 Beal, 1990, Kynurenine pathway measurements in Huntington's disease striatum: evidence for reduced formation of kynurenic acid, J. Neurochem., 55, 1327, 10.1111/j.1471-4159.1990.tb03143.x Beal, 1992, Kynurenic acid concentrations are reduced in Huntington's disease cerebral cortex, J. Neurol. Sci., 108, 80, 10.1016/0022-510X(92)90191-M Beck, 2004, Somatic and germline mosaicism in sporadic early-onset Alzheimer’s disease, Hum. Mol. Genet., 13, 1219, 10.1093/hmg/ddh134 Behan, 2002, Enhanced neuronal damage by co-administration of quinolinic acid and free radicals: and protection by adenosine A2A receptor antagonists, Br. J. Pharmacol., 135, 1435, 10.1038/sj.bjp.0704613 Behan, 1999, Oxidative stress as a mechanism for quinolinic acid-induced hippocampal damage: protection by melatonin and deprenyl, Br. J. Pharmacol., 128, 1754, 10.1038/sj.bjp.0702940 Behan, 1999, Oxidative stress as a mechanism for quinolinic acid-induced hippocampal damage: protection by melatonin and deprenyl, Br. J. Pharmacol., 128, 1754, 10.1038/sj.bjp.0702940 Berg, 2014, Time to redefine PD?: Introductory statement of the MDS Task Force on the definition of Parkinson's disease, Mov. Disord., 29, 454, 10.1002/mds.25844 Bessede, 2014, Aryl hydrocarbon receptor control of a disease tolerance defence pathway, Nature, 511, 184, 10.1038/nature13323 Bordelon, 1997, Energetic dysfunction in quinolinic acid-lesioned rat striatum, J. Neurochem., 69, 1629, 10.1046/j.1471-4159.1997.69041629.x Bordelon, 1998, Effects of intrastriatal injection of quinolinic acid on electrical activity and extracellular ion concentrations in rat striatum in vivo, Neuroscience, 83, 459, 10.1016/S0306-4522(97)00421-1 Braak, 2003, Staging of brain pathology related to sporadic Parkinson's disease, Neurobiol. Aging, 24, 197, 10.1016/S0197-4580(02)00065-9 Braak, 2006, Pathology associated with sporadic Parkinson's disease–where does it end?, J. Neural Transm. Suppl., 89 Braidy, 2009, Mechanism for quinolinic acid cytotoxicity in human astrocytes and neurons, Neurotox. Res., 16, 77, 10.1007/s12640-009-9051-z Braidy, 2009, Effects of kynurenine pathway metabolites on intracellular NAD+ synthesis and cell death in human primary astrocytes and neurons, Int. J. Trypto. Res, 2, 61, 10.4137/IJTR.S2318 Braidy, 2010, Neuroprotective effects of naturally occurring polyphenols on quinolinic acid-induced excitotoxicity in human neurons, FEBS J., 277, 368, 10.1111/j.1742-4658.2009.07487.x Braidy, 2014, Changes in Cathepsin D and Beclin-1 mRNA and protein expression by the excitotoxin quinolinic acid in human astrocytes and neurons, Metab. Brain Dis., 29, 873, 10.1007/s11011-014-9557-9 Brundin, 2011, Can alpha-synuclein be targeted in novel therapies for Parkinson's disease?, Expert Rev. Neurother., 11, 917, 10.1586/ern.11.73 Buchman, 2012, Nigral pathology and Parkinsonian signs in elders without Parkinson disease, Ann. Neurol., 71, 258, 10.1002/ana.22588 Butler, 1997, The effects of reversible inactivation of the subthalamo-pallidal pathway on the behaviour of naive and hemiparkinsonian monkeys, J. Clin. Neurosci., 4, 218, 10.1016/S0967-5868(97)90076-X Cabezas, 2014, Astrocytic modulation of blood brain barrier: perspectives on Parkinson's disease, Front. Cell. Neurosci., 8, 211, 10.3389/fncel.2014.00211 Calon, 2002, Alteration of glutamate receptors in the striatum of dyskinetic 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated monkeys following dopamine agonist treatment, ProgressNeuro-Psychopharmacol. Biol. Psychiatr., 26, 127, 10.1016/S0278-5846(01)00237-8 Cammer, 2001, Oligodendrocyte killing by quinolinic acid in vitro, Brain Res., 896, 157, 10.1016/S0006-8993(01)02017-0 Cammer, 2002, Apoptosis of oligodendrocytes in secondary cultures from neonatal rat brains, Neurosci. Lett., 327, 123, 10.1016/S0304-3940(02)00392-0 Capuron, 2011, Immune system to brain signaling: neuropsychopharmacological implications, Pharmacol. Ther., 130, 226, 10.1016/j.pharmthera.2011.01.014 Ceresoli-Borroni, 2007, Perinatal kynurenine 3-hydroxylase inhibition in rodents: pathophysiological implications, J. Neurosci. Res., 85, 845, 10.1002/jnr.21183 Chen, 2009, Kynurenine pathway metabolites in humans: disease and healthy states, Int. J. Trypto. Res., 1, 1 Chen, 2009, Kynurenine pathway metalbolites in humans: disease and healthy states, IJTR, 2, 1, 10.4137/IJTR.S2097 Chen, 2010, Characterization of the kynurenine pathway in NSC-34 cell line: implications for amyotrophic lateral sclerosis, J. Neurochem., 118, 816, 10.1111/j.1471-4159.2010.07159.x Chen, 2010, The kynurenine pathway and inflammation in amyotrophic lateral sclerosis, Neurotox. Res., 18, 132, 10.1007/s12640-009-9129-7 Chiarugi, 2001, Similarities and differences in the neuronal death processes activated by 3OH-kynurenine and quinolinic acid, J. Neurochem., 77, 1310, 10.1046/j.1471-4159.2001.00335.x Chu, 2014, LC3 binds externalized cardiolipin on injured mitochondria to signal mitophagy in neurons: implications for Parkinson disease, Autophagy, 10, 376, 10.4161/auto.27191 Collier, 2011, Ageing as a primary risk factor for Parkinson's disease: evidence from studies of non-human primates, Nat. Rev. Neurosci., 12, 359, 10.1038/nrn3039 Copeland, 2013, Actions of Xanthurenic acid a putative endogenous Group II metabotropic glutamate receptor agonist, on sensory transmission in the thalamus, Neuropharmacology, 66, 133, 10.1016/j.neuropharm.2012.03.009 Coutinho, 2014, The kynurenine pathway is involved in bacterial meningitis, J. Neuroinflammation, 11, 169, 10.1186/s12974-014-0169-4 Czlonkowska, 1996, Microglial reaction in MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) induced Parkinson's disease mice model, Neurodegener. J. Neurodegenerative Disord. Neuroprot. Neuroregener., 5, 137 Dahm, 2006, Persistent S-nitrosation of complex I and other mitochondrial membrane proteins by S-nitrosothiols but not nitric oxide or peroxynitrite: implications for the interaction of nitric oxide with mitochondria, J. Biol. Chem., 281, 10056, 10.1074/jbc.M512203200 de Carvalho, 1996, The endogenous agonist quinolinic acid and the non endogenous homoquinolinic acid discriminate between NMDAR2 receptor subunits, Neurochem. Int., 28, 445, 10.1016/0197-0186(95)00091-7 Deleidi, 2013, The role of inflammation in sporadic and familial Parkinson's disease, Cell. Mol. Life Sci., 70, 4259, 10.1007/s00018-013-1352-y Demeter, 2012, A novel kynurenic acid analog (SZR104) inhibits pentylenetetrazole-induced epileptiform seizures. An electrophysiological study: related to kynurenine, J. Neural Transm., 119, 151, 10.1007/s00702-011-0755-x Depienne, 2007, A de novo SPAST mutation leading to somatic mosaicism is associated with a later age at onset in HSP, Neurogenetics, 8, 231, 10.1007/s10048-007-0090-4 DiNatale, 2010, Kynurenic acid is a potent endogenous aryl hydrocarbon receptor ligand that synergistically induces interleukin-6 in the presence of inflammatory signaling, Toxicol. Sci., 115, 89, 10.1093/toxsci/kfq024 Downer, 2013, Differential role of Dok1 and Dok2 in TLR2-induced inflammatory signaling in glia, Mol. Cell. Neurosci., 56, 148, 10.1016/j.mcn.2013.04.007 Duty, 2010, Therapeutic potential of targeting group III metabotropic glutamate receptors in the treatment of Parkinson's disease, Br. J. Pharmacol., 161, 271, 10.1111/j.1476-5381.2010.00882.x Eastman, 1989, Cytotoxicity of 3-hydroxykynurenine in a neuronal hybrid cell line, Brain Res., 495, 225, 10.1016/0006-8993(89)90216-3 Eastman, 1990, The role of hydrogen peroxide in the in vitro cytotoxicity of 3-hydroxykynurenine, Neurochem. Res., 15, 1101, 10.1007/BF01101711 Emmrich, 2013, Rotenone induces neuronal death by microglial phagocytosis of neurons, FEBS J., 280, 5030, 10.1111/febs.12401 Erhardt, 2013, Connecting inflammation with glutamate agonism in suicidality, Neuropsychopharmacology, 38, 743, 10.1038/npp.2012.248 Essa, 2013, Role of NAD(+) oxidative stress, and tryptophan metabolism in autism spectrum disorders, Int J Tryptophan Res, 6, 15 Fazio, 2012, Cinnabarinic acid an endogenous metabolite of the kynurenine pathway, activates type 4 metabotropic glutamate receptors, Mol. Pharmacol., 81, 643, 10.1124/mol.111.074765 Fernandez-Gomez, 2005, Involvement of mitochondrial potential and calcium buffering capacity in minocycline cytoprotective actions, Neuroscience, 133, 959, 10.1016/j.neuroscience.2005.03.019 Fernandez-Gomez, 2006, Pyruvate protects cerebellar granular cells from 6-hydroxydopamine-induced cytotoxicity by activating the Akt signaling pathway and increasing glutathione peroxidase expression, Neurobiol. Dis., 24, 296, 10.1016/j.nbd.2006.07.005 Finsterwald, 2015, Astrocytes: new targets for the treatment of neurodegenerative diseases, Curr. Pharm. Des., 21, 3570, 10.2174/1381612821666150710144502 Forno, 1992, Astrocytes and parkinson's disease, Prog. Brain Res., 94, 429, 10.1016/S0079-6123(08)61770-7 Foster, 1983, On the excitotoxic properties of quinolinic acid 2, 3-piperidine dicarboxylic acids and structurally related compounds, Neuropharmacology, 22, 1331, 10.1016/0028-3908(83)90221-6 Foster, 1984, Kynurenic acid blocks neurotoxicity and seizures induced in rats by the related brain metabolite quinolinic acid, Neurosci. Lett., 48, 273, 10.1016/0304-3940(84)90050-8 Fujigaki, 2001, Lipopolysaccharide induction of indoleamine 2,3-dioxygenase is mediated dominantly by an IFN-gamma-independent mechanism, Eur. J. Immunol., 31, 2313, 10.1002/1521-4141(200108)31:8<2313::AID-IMMU2313>3.0.CO;2-S Fukui, 1991, Blood-brain barrier transport of kynurenines: implications for brain synthesis and metabolism, J. Neurochem., 56, 2007, 10.1111/j.1471-4159.1991.tb03460.x Fukuyama, 2014, Zonisamide regulates basal ganglia transmission via astroglial kynurenine pathway, Neuropharmacology, 76, 137, 10.1016/j.neuropharm.2013.08.002 Galluzzi, 2014, Organelle-specific initiation of cell death, Nat. Cell Biol., 16, 728, 10.1038/ncb3005 Gao, 2013, Rotenone directly induces BV2 cell activation via the p38 MAPK pathway, PLoS One, 8, e72046, 10.1371/journal.pone.0072046 Garcia-Esparcia, 2015, Purine metabolism gene deregulation in Parkinson’s disease, Neuropathol. Appl. Neurobiol., 41, 926, 10.1111/nan.12221 Gellert, 2011, Neuroprotection with a new kynurenic acid analog in the four-vessel occlusion model of ischemia, Eur. J. Pharmacol., 667, 182, 10.1016/j.ejphar.2011.05.069 Ghorayeb, 2001, Simultaneous intrastriatal 6-hydroxydopamine and quinolinic acid injection: a model of early-stage striatonigral degeneration, Exp. Neurol., 167, 133, 10.1006/exnr.2000.7535 Goda, 1996, Quinolinic acid and active oxygens: possible contribution of active Oxygens during cell death in the brain, Adv. Exp. Med. Biol., 398, 247, 10.1007/978-1-4613-0381-7_38 Godbolt, 2004, A presenilin 1 R278I mutation presenting with language impairment, Neurology, 63, 1702, 10.1212/01.WNL.0000143060.98164.1A Goedert, 2013, 100 years of Lewy pathology, Nat. Rev. Neurol., 9, 13, 10.1038/nrneurol.2012.242 Goldstein, 2000, 3- hydroxykynurenine and 3-Hydroxyanthranilic acid generate hydrogen peroxide and promote Œ ± −Crystallin cross-Linking by metal ion reduction, Ć, Biochemistry, 39, 7266, 10.1021/bi992997s Goldstein, 2000, 3- Hydroxykynurenine and 3-hydroxyanthranilic acid generate hydrogen peroxide and promote alpha-crystallin cross-linking by metal ion reduction, Biochemistry, 39, 7266, 10.1021/bi992997s Gonzalez, 2013, Dopamine receptor D3 expressed on CD4+ T cells favors neurodegeneration of dopaminergic neurons during Parkinson's disease, J. Immunol., 190, 5048, 10.4049/jimmunol.1203121 Graham, 1990, Injection of excitatory amino acid antagonists into the medial pallidal segment of a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) treated primate reverses motor symptoms of parkinsonism, Life Sci., 47, PL91, 10.1016/0024-3205(90)90376-3 Grant, 2009, The physiological action of picolinic acid in the human brain, Int. J. Tryptophan Res., 2009, 71 Gratwicke, 2015, Parkinson's disease dementia: a neural networks perspective, Brain, 138, 1454, 10.1093/brain/awv104 Gregoire, 2008, Prolonged kynurenine 3-hydroxylase inhibition reduces development of levodopa-induced dyskinesias in Parkinsonian monkeys, Behav. Brain Res., 186, 161, 10.1016/j.bbr.2007.08.007 Groves, 2013, Dynamic O-GlcNAcylation and its roles in the cellular stress response and homeostasis, Cell Stress Chaperones, 18, 535, 10.1007/s12192-013-0426-y Guidetti, 1999, 3-Hydroxykynurenine potentiates quinolinate but not NMDA toxicity in the rat striatum, Eur. J. Neurosci., 11, 3857, 10.1046/j.1460-9568.1999.00806.x Guillemin, 2002, Implications of the kynurenine pathway and quinolinic acid in Alzheimer's disease, Redox Rep., 7, 199, 10.1179/135100002125000550 Guillemin, 2002, Implications of the kynurenine pathway and quinolinic acid in Alzheimer's disease, Redox Rep., 7, 199, 10.1179/135100002125000550 Guillemin, 2007, Chronic HIV infection leads to an Alzheimer's disease like illness. Involvement of the kynurenine pathway, 324 Guillemin, 2001, Kynurenine pathway metabolism in human astrocytes: a paradox for neuronal protection, J. Neurochem., 78, 1, 10.1046/j.1471-4159.2001.00498.x Guillemin, 2001, Bamyloid peptide 1–42 induces human macrophages to produce the neurotoxin quinolinic acid, J. Neuroimmunol., 118 Guillemin, 2003, Quinolinic acid upregulates chemokine production and chemokine receptor expression in astrocytes, Glia, 41, 371, 10.1002/glia.10175 Guillemin, 2003, Expression of the kynurenine pathway enzymes in human microglia and macrophages, Adv. Exp. Med. Biol., 527, 105, 10.1007/978-1-4615-0135-0_12 Guillemin, 2005, Indoleamine 2,3 dioxygenase and quinolinic acid in plaque and neurons in post-mortem brain tissue from Alzheimer‘s disease and control cases, Neuropathol. Appl. Neurobiol., 31, 395, 10.1111/j.1365-2990.2005.00655.x Guillemin, 2005, Involvement of quinolinic acid in AIDS dementia complex, Neurotox. Res., 7, 103, 10.1007/BF03033781 Guillemin, 2005, Expression of indoleamine 2,3-dioxygenase and production of quinolinic acid by human microglia astrocytes, and neurons, Glia, 49, 15, 10.1002/glia.20090 Guillemin, 2005, Quinolinic acid selectively induces apoptosis of human astrocytes: potential role in AIDS dementia complex, J. Neuroinflammation, 2, 16, 10.1186/1742-2094-2-16 Guillemin, 2006, Implications for the kynurenine pathway and quinolinic acid in amyotrophic lateral sclerosis, Neurodegenerative Dis., 2, 166, 10.1159/000089622 Guillemin, 2007, Mass spectrometric detection of quinolinic acid in microdissected Alzheimer disease plaques, Int. Congress Series, 1304, 404, 10.1016/j.ics.2007.07.012 Guillemin, 2007, Characterization of the kynurenine pathway in human neurons, J. Neurosci., 27, 12884, 10.1523/JNEUROSCI.4101-07.2007 Guillemin, 2012, Quinolinic acid the inescapable neurotoxin, FEBS J., 279, 1356, 10.1111/j.1742-4658.2012.08485.x Guridi, 1996, Subthalamotomy in Parkinsonian monkeys: behavioural and biochemical, Brain, 119, 1717, 10.1093/brain/119.5.1717 Halliday, 2011, Glia: initiators and progressors of pathology in Parkinson's disease, Mov. Disord., 26, 6, 10.1002/mds.23455 Hamann, 2008, Effects of the kynurenine 3-hydroxylase inhibitor Ro 61–8048 after intrastriatal injections on the severity of dystonia in the dt sz mutant, Eur. J. Pharmacol., 586, 156, 10.1016/j.ejphar.2008.02.052 Han, 2015, Nitric oxide induction of parkin translocation in PTEN-induced putative kinase 1 (PINK1) deficiency: functional role of neuronal nitric oxide synthase during mitophagy, J. Biol. Chem., 290, 10325, 10.1074/jbc.M114.624767 Hartai, 2005, Kynurenine metabolism in multiple sclerosis, Acta Neurol. Scand., 112, 93, 10.1111/j.1600-0404.2005.00442.x Hartai, 2005, Kynurenine metabolism in plasma and in red blood cells in Parkinson's disease, J. Neurol. Sci., 239, 31, 10.1016/j.jns.2005.07.006 Hartai, 2005, Kynurenine metabolism in plasma and in red blood cells in Parkinson's disease, J. Neurol. Sci., 239, 31, 10.1016/j.jns.2005.07.006 Herrero, 2015, Inflammation in Parkinson's disease: role of glucocorticoids, Front. Neuroanat., 9, 32, 10.3389/fnana.2015.00032 Herrero, 1996, GAD mRNA expression in medial pallidal neurons in MPTP-treated monkey and Parkinson’s disease, Neurology, 47, 219, 10.1212/WNL.47.1.219 Hill-Burns, 2011, Evidence for more than one Parkinson's disease-associated variant within the HLA region, PLoS One, 6, e27109, 10.1371/journal.pone.0027109 Hilmas, 2001, The brain metabolite kynurenic acid inhibits alpha7 nicotinic receptor activity and increases non-alpha7 nicotinic receptor expression: physiopathological implications, J. Neurosci., 21, 7463, 10.1523/JNEUROSCI.21-19-07463.2001 Holtze, 2008, Induction of the kynurenine pathway by neurotropic influenza a virus infection, J. Neurosci. Res., 86, 3674, 10.1002/jnr.21799 Hyun, 2002, 2002. Effect of wild-type or mutant Parkin on oxidative damage, nitric oxide, antioxidant defenses, and the proteasome, J. Biol. Chem., 277, 28572, 10.1074/jbc.M200666200 Iwahashi, 1988, Superoxide-Dismutase enhances the formation of hydroxyl radicals in the reaction of 3-Hydroxyanthranilic acid with molecular-Oxygen, Biochem. J., 251, 893, 10.1042/bj2510893 Jang, 2009, Highly pathogenic H5N1 influenza virus can enter the central nervous system and induce neuroinflammation and neurodegeneration, Proc. Natl. Acad. Sci. U. S. A., 106, 14063, 10.1073/pnas.0900096106 Jang, 2009, Viral parkinsonism, Biochim. Biophys. Acta, 1792, 714, 10.1016/j.bbadis.2008.08.001 Jauch, 1995, Dysfunction of brain kynurenic acid metabolism in Huntington's disease: focus on kynurenine aminotransferases, J. Neurol. Sci., 130, 39, 10.1016/0022-510X(94)00280-2 Jhamandas, 1990, Quinolinate-induced cortical cholinergic damage: modulation by tryptophan metabolites, Brain Res., 529, 185, 10.1016/0006-8993(90)90826-W Johnson, 2009, Glutamate receptors as therapeutic targets for Parkinson's disease, CNS Neurol. Disord. Drug Targets, 8, 475, 10.2174/187152709789824606 Jones, 2013, The kynurenine pathway in stem cell biology, Int. J. Tryptophan. Res., 6, 57, 10.4137/IJTR.S12626 Kegel, 2014, Imbalanced kynurenine pathway in schizophrenia, Int. J. Tryptophan. Res., 7, 15, 10.4137/IJTR.S16800 Khan, 2013, Protection of MPTP-induced neuroinflammation and neurodegeneration by Pycnogenol, Neurochem. Int., 62, 379, 10.1016/j.neuint.2013.01.029 Kieburtz, 2013, Parkinson's disease: evidence for environmental risk factors, Mov. Disord., 28, 8, 10.1002/mds.25150 Kim, 2014, Hypothesis: somatic mosaicism and Parkinson disease, Exp Neurobiol, 23, 271, 10.5607/en.2014.23.4.271 Knyihar-Csillik, 2004, Decreased expression of kynurenine aminotransferase-I (KAT-I) in the substantia nigra of mice after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) treatment, Neuroscience, 126, 899, 10.1016/j.neuroscience.2004.04.043 Knyihar-Csillik, 2006, Effect of 6-hydroxydopamine treatment on kynurenine aminotransferase-I (KAT-I) immunoreactivity of neurons and glial cells in the rat substantia nigra, Acta Neuropathol. (Berl.), 112, 127, 10.1007/s00401-006-0086-4 Knyihar-Csillik, 2006, Effect of 6-hydroxydopamine treatment on kynurenine aminotransferase-I (KAT-I) immunoreactivity of neurons and glial cells in the rat substantia nigra, Acta Neuropathol., 112, 127, 10.1007/s00401-006-0086-4 Knyihar-Csillik, 2008, The kynurenate analog SZR-72 prevents the nitroglycerol-induced increase of c-fos immunoreactivity in the rat caudal trigeminal nucleus: comparative studies of the effects of SZR-72 and kynurenic acid, Neurosci. Res., 61, 429, 10.1016/j.neures.2008.04.009 Ko, 2014, Effects of L-tryptophan on L-DOPA-induced dyskinesia in the L-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated macaque model of Parkinson's disease, Neurosci. Lett., 566, 72, 10.1016/j.neulet.2014.02.027 Kravzov, 1993, Protective effect of probenecid on circling behavior of rats with unilateral quinollinic acid induced striatal lesions, Proc. West. Pharmacol. Soc., 36, 255 Kubesova, 2015, Biochemical, histopathological and morphological profiling of a rat model of early immune stimulation: relation to psychopathology, PLoS One, 10, e0115439, 10.1371/journal.pone.0115439 Kumar, 2004, Characterization of striatal cultures with the effect of QUIN and NMDA, Neurosci. Res., 49, 29, 10.1016/j.neures.2004.01.011 Lee do, 2008, Kynurenic acid attenuates MPP(+)-induced dopaminergic neuronal cell death via a Bax-mediated mitochondrial pathway, Eur. J. Cell Biol., 87, 389, 10.1016/j.ejcb.2008.03.003 Lee, 2010, Characterisation of the expression of NMDA receptors in human astrocytes, PLoS One, 5, e14123, 10.1371/journal.pone.0014123 Levy, 1997, Reevaluation of the functional anatomy of the basal ganglia in normal and Parkinsonian states, Neuroscience, 76, 335, 10.1016/S0306-4522(96)00409-5 Lewitt, 2013, Parkinson's Disease 3- hydroxykynurenine and other Parkinson's disease biomarkers discovered by metabolomic analysis, Mov. Disord., 28, 1653, 10.1002/mds.25555 Licker, 2012, Proteomic profiling of the substantia nigra demonstrates CNDP2 overexpression in Parkinson's disease, J. Proteomics, 75, 4656, 10.1016/j.jprot.2012.02.032 Lill, 2012, Comprehensive research synopsis and systematic meta-analyses in Parkinson's disease genetics: the PDGene database, PLoS Genet., 8, e1002548, 10.1371/journal.pgen.1002548 Lim, 2007, Characterization of the kynurenine pathway in primary human oligodendrocytes, Int. Congress Series, 1304, 213, 10.1016/j.ics.2007.07.011 Lim, 2010, Understanding the roles of the kynurenine pathway in multiple sclerosis progression, Int. J. Tryptophan. Res., 3, 157, 10.4137/IJTR.S4294 Lindqvist, 2012, Non-motor symptoms in patients with Parkinson's disease—correlations with inflammatory cytokines in serum, PLoS One, 7, e47387, 10.1371/journal.pone.0047387 Lowe, 2014, Identification of cinnabarinic acid as a novel endogenous aryl hydrocarbon receptor ligand that drives IL-22 production, PLoS One, 9, e87877, 10.1371/journal.pone.0087877 Lu, 2014, Uncoupling protein 2 deficiency aggravates astrocytic endoplasmic reticulum stress and nod-like receptor protein 3 inflammasome activation, Neurobiol. Aging, 35, 421, 10.1016/j.neurobiolaging.2013.08.015 Luchowski, 2002, 1-Methyl-4-phenylpyridinium and 3-nitropropionic acid diminish cortical synthesis of kynurenic acid via interference with kynurenine aminotransferases in rats, Neurosci. Lett., 330, 49, 10.1016/S0304-3940(02)00735-8 Lugo-Huitron, 2011, On the antioxidant properties of kynurenic acid: free radical scavenging activity and inhibition of oxidative stress, Neurotoxicol. Teratol., 33, 538, 10.1016/j.ntt.2011.07.002 Lugo-Huitron, 2013, Quinolinic acid: an endogenous neurotoxin with multiple targets, Oxid. Med. Cell. Longevity, 2013, 104024, 10.1155/2013/104024 Marin, 2000, Non-NMDA receptor-mediated mechanisms are involved in levodopa-induced motor response alterations in Parkinsonian rats, Synapse, 36, 267, 10.1002/(SICI)1098-2396(20000615)36:4<267::AID-SYN3>3.0.CO;2-Y Massudi, 2012, NAD+ metabolism and oxidative stress: the golden nucleotide on a crown of thorns, Redox Rep., 17, 28, 10.1179/1351000212Y.0000000001 McGeer, 1984, Neurotoxic effects of endogenous materials: quinolinic acid, L-pyroglutamic acid, and thyroid releasing hormone, Exp. Neurol., 86, 410, 10.1016/0014-4886(84)90197-3 McNally, 2008, Inflammation glutamate, and glia in depression: a literature review, CNS Spectr., 13, 501, 10.1017/S1092852900016734 Melillo, 1996, Immunobiology of picolinic acid, Adv. Exp. Med. Biol., 398, 135, 10.1007/978-1-4613-0381-7_22 Mellor, 2003, Cutting edge: induced indoleamine 2,3 dioxygenase expression in dendritic cell subsets suppresses T cell clonal expansion, J. Immunol., 171, 1652, 10.4049/jimmunol.171.4.1652 Merino, 1999, The non-NMDA glutamate receptor antagonists 6-cyano-7-nitroquinoxaline-2,3-dione and 2,3-dihydroxy-6-nitro-7-sulfamoylbenzo(f)quinoxaline but not NMDA antagonists, block the intrastriatal neurotoxic effect of MPP+, J. Neurochem., 73, 750, 10.1046/j.1471-4159.1999.0730750.x Meyer, 1992, Effects of interferons beta or gamma on neopterin biosynthesis and tryptophan degradation by human alveolar macrophages in vitro: synergy with lipopolysaccharide, Am. J. Respir. Cell Mol. Biol., 6, 639, 10.1165/ajrcmb/6.6.639 Mezrich, 2010, An interaction between kynurenine and the aryl hydrocarbon receptor can generate regulatory T cells, J. Immunol., 185, 3190, 10.4049/jimmunol.0903670 Miranda, 1997, Protection against quinolinic acid-mediated excitotoxicity in nigrostriatal dopaminergic neurons by endogenous kynurenic acid, Neuroscience, 78, 967, 10.1016/S0306-4522(96)00655-0 Moffett, 2003, Tryptophan and the immune response, Immunol. Cell Biol., 81, 247, 10.1046/j.1440-1711.2003.t01-1-01177.x Moffett, 1997, Quinolinate immunoreactivity in experimental rat brain tumors is present in macrophages but not in astrocytes, Exp. Neurol., 144, 287, 10.1006/exnr.1996.6365 Morin, 2014, Interaction of adenosine receptors with other receptors from therapeutic perspective in parkinson's disease, Adenosine Receptors Neurol. Psychiatry, 119, 151, 10.1016/B978-0-12-801022-8.00007-6 Morin, 2014, Modeling dyskinesia in animal models of Parkinson disease, Exp. Neurol., 256, 105, 10.1016/j.expneurol.2013.01.024 Mostafalou, 2013, Pesticides and human chronic diseases: evidences mechanisms, and perspectives, Toxicol. Appl. Pharmacol., 268, 157, 10.1016/j.taap.2013.01.025 Muller, 2011, Kynurenine pathway in schizophrenia: pathophysiological and therapeutic aspects, Curr. Pharm. Des., 17, 130, 10.2174/138161211795049552 Munn, 2004, IDO and tolerance to tumors, Trends Mol. Med., 10, 15, 10.1016/j.molmed.2003.11.003 Németh, 2006, Kynurenines, Parkinson's disease and other neurodegenerative disorders: preclinical and clinical studies, J. Neural Transm. Suppl., 285 Nakao, 1996, Antioxidant treatment protects striatal neurons against excitotoxic insults, Neuroscience, 73, 185, 10.1016/0306-4522(96)00034-6 Nalls, 2014, Large-scale meta-analysis of genome-wide association data identifies six new risk loci for Parkinson's disease, Nat. Genet., 46, 989, 10.1038/ng.3043 Nalls, 2015, NeuroX, a fast and efficient genotyping platform for investigation of neurodegenerative diseases, Neurobiol. Aging, 36, 10.1016/j.neurobiolaging.2014.07.028 Nam, 2015, TRPV1 on astrocytes rescues nigral dopamine neurons in Parkinson's disease via CNTF, Brain, 138, 3610, 10.1093/brain/awv297 Naviaux, 2014, Metabolic features of the cell danger response, Mitochondrion, 16, 7, 10.1016/j.mito.2013.08.006 Nguyen, 2002, Innate immunity: the missing link in neuroprotection and neurodegeneration?, Nat. Rev. Neurosci., 3, 216, 10.1038/nrn752 Nicoletti, 2011, Metabotropic glutamate receptors: from the workbench to the bedside, Neuropharmacology, 60, 1017, 10.1016/j.neuropharm.2010.10.022 Niranjan, 2014, The role of inflammatory and oxidative stress mechanisms in the pathogenesis of Parkinson's disease: focus on astrocytes, Mol. Neurobiol., 49, 28, 10.1007/s12035-013-8483-x Ogawa, 1992, Kynurenine pathway abnormalities in Parkinson's disease, Neurology, 42, 1702, 10.1212/WNL.42.9.1702 Orlando, 2001, The role of group I and group II metabotropic glutamate receptors in modulation of striatal NMDA and quinolinic acid toxicity, Exp. Neurol., 167, 196, 10.1006/exnr.2000.7542 Ouattara, 2009, Implication of NMDA receptors in the antidyskinetic activity of cabergoline CI-1041, and Ro 61–8048 in MPTP monkeys with levodopa-induced dyskinesias, J. Mol. Neurosci., 38, 128, 10.1007/s12031-008-9137-8 Owe-Young, 2008, Kynurenine pathway metabolism in human blood-brain-barrier cells: implications for immune tolerance and neurotoxicity, J. Neurochem., 105, 1346, 10.1111/j.1471-4159.2008.05241.x Pérez-De La Cruz, 2011, Quinolinic acid, an endogenous molecule combining excitotoxicity, oxidative stress and other toxic mechanisms, FEBS J. Pemberton, 1997, Quinolinic acid production by macrophages stimulated with IFN-gamma TNF-alpha, and IFN-alpha, J. Interferon Cytokine Res., 17, 589, 10.1089/jir.1997.17.589 Perez-De La Cruz, 2007, Kynurenine pathway and disease: an overview, CNS Neurol. Disord. Drug Targets, 6, 398, 10.2174/187152707783399229 Perez-De La Cruz, 2009, Targeting oxidative/nitrergic stress ameliorates motor impairment: and attenuates synaptic mitochondrial dysfunction and lipid peroxidation in two models of Huntington's disease, Behav. Brain Res., 199, 210, 10.1016/j.bbr.2008.11.037 Perez-De La Cruz, 2012, Quinolinic Acid an endogenous molecule combining excitotoxicity, oxidative stress and other toxic mechanisms, Int. J. Tryptophan Res., 5, 1 Perkins, 1982, An iontophoretic investigation of the actions of convulsant kynurenines and their interaction with the endogenous excitant quinolinic acid, Brain Res., 247, 184, 10.1016/0006-8993(82)91048-4 Perkins, 1983, Pharmacology and regional variations of quinolinic acid-evoked excitations in the rat central nervous system, J. Pharm. Exp. Ther., 226, 551 Peterson, 2012, Oxidative stress and microglial cells in Parkinson's disease, Mediators Inflamm., 2012, 401264, 10.1155/2012/401264 Phillipson, 2014, Management of the aging risk factor for Parkinson's disease, Neurobiol. Aging, 35, 847, 10.1016/j.neurobiolaging.2013.10.073 Pieper, 2008, Different methylation of the TNF-alpha promoter in cortex and substantia nigra: implications for selective neuronal vulnerability, Neurobiol. Dis., 32, 521, 10.1016/j.nbd.2008.09.010 Pierozan, 2010, Acute intrastriatal administration of quinolinic acid provokes hyperphosphorylation of cytoskeletal intermediate filament proteins in astrocytes and neurons of rats, Exp. Neurol., 224, 188, 10.1016/j.expneurol.2010.03.009 Pittaluga, 2001, N-methyl-D-aspartate receptors mediating hippocampal noradrenaline and striatal dopamine release display differential sensitivity to quinolinic acid the HIV-1 envelope protein gp120, external pH and protein kinase C inhibition, J. Neurochem., 76, 139, 10.1046/j.1471-4159.2001.00057.x Platenik, 2001, Quinolinic acid-iron(ii) complexes: slow autoxidation: but enhanced hydroxyl radical production in the fenton reaction, Free Radic. Res., 34, 445, 10.1080/10715760100300391 Pomplun, 2015, Rational design and asymmetric synthesis of potent and neurotrophic ligands for FK506-binding proteins (FKBPs), Angew. Chem., 54, 345, 10.1002/anie.201408776 Portela, 2010, Epigenetic modifications and human disease, Nat. Biotechnol., 28, 1057, 10.1038/nbt.1685 Prajapati, 2015, TNF-alpha regulates miRNA targeting mitochondrial complex-I and induces cell death in dopaminergic cells, Biochim. Biophys. Acta, 1852, 451, 10.1016/j.bbadis.2014.11.019 Pringsheim, 2014, The prevalence of Parkinson's disease: a systematic review and meta-analysis, Mov. Disord., 29, 1583, 10.1002/mds.25945 Proukakis, 2014, Analysis of Parkinson's disease brain-derived DNA for alpha-synuclein coding somatic mutations, Mov. Disord., 29, 1060, 10.1002/mds.25883 Rahman, 2009, The excitotoxin quinolinic acid induces tau phosphorylation in human neurons, PLoS One, 4, e6344, 10.1371/journal.pone.0006344 Rajda, 2007, Kynurenines, redox disturbances and neurodegeneration in multiple sclerosis, J. Neural Transm. Suppl., 323 Recasens, 2014, Alpha-synuclein spreading in Parkinson's disease, Front. Neuroanat., 8, 159, 10.3389/fnana.2014.00159 Reeve, 2014, Ageing and Parkinson's disease: why is advancing age the biggest risk factor?, Ageing Res. Rev., 14, 19, 10.1016/j.arr.2014.01.004 Reynolds, 1998, Changes in blood-brain barrier permeability following neurotoxic lesions of rat brain can be visualised with trypan blue, J. Neurosci. Methods, 79, 115, 10.1016/S0165-0270(97)00168-4 Ribeiro, 2006, Evidence that quinolinic acid severely impairs energy metabolism through activation of NMDA receptors in striatum from developing rats, J. Neurochem., 99, 1531, 10.1111/j.1471-4159.2006.04199.x Rios, 1991, Quinolinic acid is a potent lipid peroxidant in rat brain homogenates, Neurochem. Res., 16, 1139, 10.1007/BF00966592 Saito, 1993, Kynurenine pathway enzymes in brain: responses to ischemic brain injury versus systemic immune activation, J. Neurochem., 61, 2061, 10.1111/j.1471-4159.1993.tb07443.x Samadi, 2005, Effect of kynurenine 3-hydroxylase inhibition on the dyskinetic and antiparkinsonian responses to levodopa in Parkinsonian monkeys, Mov. Disord., 20, 792, 10.1002/mds.20596 Sampedro, 2014, Glutamatergic receptors in Parkinson’s disease, 1311 Sanberg, 1989, The quinolinic acid model of Huntington's disease: locomotor abnormalities, Exp. Neurol., 105, 45, 10.1016/0014-4886(89)90170-2 Sanchez-Guajardo, 2013, alpha-Synuclein vaccination prevents the accumulation of parkinson disease-like pathologic inclusions in striatum in association with regulatory T cell recruitment in a rat model, J. Neuropathol. Exp. Neurol., 72, 624, 10.1097/NEN.0b013e31829768d2 Santamaria, 1993, MK-801 an N-methyl-D-aspartate receptor antagonist, blocks quinolinic acid-induced lipid peroxidation in rat corpus striatum, Neurosci. Lett., 159, 51, 10.1016/0304-3940(93)90796-N Santamaria, 2001, Quinolinic acid induces oxidative stress in rat brain synaptosomes, Neuroreport, 12, 871, 10.1097/00001756-200103260-00049 Santamaria, 2001, In vivo hydroxyl radical formation after quinolinic acid infusion into rat corpus striatum, Neuroreport, 12, 2693, 10.1097/00001756-200108280-00020 Savitz, 2015, Putative neuroprotective and neurotoxic kynurenine pathway metabolites are associated with hippocampal and amygdalar volumes in subjects with major depressive disorder, Neuropsychopharmacology, 40, 463, 10.1038/npp.2014.194 Schapira, 2014, Slowing of neurodegeneration in Parkinson's disease and Huntington's disease: future therapeutic perspectives, Lancet, 384, 545, 10.1016/S0140-6736(14)61010-2 Schapira, 1993, Mitochondrial complex I deficiency in Parkinson's disease, Adv. Neurol., 60, 288 Schildknecht, 2013, Oxidative and nitrative alpha-synuclein modifications and proteostatic stress: implications for disease mechanisms and interventions in synucleinopathies, J. Neurochem., 125, 491, 10.1111/jnc.12226 Schurr, 1993, Quinolinate potentiates the neurotoxicity of excitatory amino acids in hypoxic neuronal tissue in vitro, Brain Res., 617, 76, 10.1016/0006-8993(93)90615-T Schwarcz, 1983, Differential vulnerability of central neurons of the rat to quinolinic acid, Neurosci. Lett., 38, 85, 10.1016/0304-3940(83)90115-5 Schwarcz, 1983, Differential vulnerability of central neurons of the rat to quinolinic acid, Neurosci. Lett., 38, 85, 10.1016/0304-3940(83)90115-5 Shear, 1998, Chronic administration of quinolinic acid in the rat striatum causes spatial learning deficits in a radial arm water maze task, Exp. Neurol., 150, 305, 10.1006/exnr.1998.6767 Silva-Adaya, 2011, Protective effect of L-kynurenine and probenecid on 6-hydroxydopamine-induced striatal toxicity in rats: implications of modulating kynurenate as a protective strategy, Neurotoxicol. Teratol., 33, 303, 10.1016/j.ntt.2010.10.002 Singh, 2011, Role of genetic polymorphisms of CYP1A1CYP3A5, CYP2C9, CYP2D6, and PON1 in the modulation of DNA damage in workers occupationally exposed to organophosphate pesticides, Toxicol. Appl. Pharmacol., 257, 84, 10.1016/j.taap.2011.08.021 Smith, 2001, Quinolinic acid is produced by macrophages stimulated platelet activating factor Nef and Tat, J. Neurovirol., 7, 56, 10.1080/135502801300069692 Smith, 2009, 5-Hydroxyanthranilic acid a tryptophan metabolite, generates oxidative stress and neuronal death via p38 activation in cultured cerebellar granule neurones, Neurotox. Res., 15, 303, 10.1007/s12640-009-9034-0 Solano, 2006, Midbrain neuronal cultures from parkin mutant mice are resistant to nitric oxide-induced toxicity, Neuropharmacology, 51, 327, 10.1016/j.neuropharm.2006.03.027 Solesio, 2012, Characterization of mitophagy in the 6-hydoxydopamine Parkinson's disease model, Toxicol. Sci., 129, 411, 10.1093/toxsci/kfs218 St'astny, 2000, Quinolinic acid enhances permeability of rat brain microvessels to plasma albumin, Brain Res. Bull., 53, 415, 10.1016/S0361-9230(00)00368-3 Steiner, 2011, Bridging the gap between the immune and glutamate hypotheses of schizophrenia and major depression: potential role of glial NMDA receptor modulators and impaired blood-brain barrier integrity, World J. Biol. Psychiatry, 1 Steiner, 2011, Severe depression is associated with increased microglial quinolinic acid in subregions of the anterior cingulate gyrus: evidence for an immune-modulated glutamatergic neurotransmission?, J. Neuroinflammation, 8, 94, 10.1186/1742-2094-8-94 Steiner, 2011, Severe depression is associated with increased microglial quinolinic acid in subregions of the anterior cingulate gyrus: evidence for an immune-modulated glutamatergic neurotransmission?, J. Neuroinflammation, 8, 1, 10.1186/1742-2094-8-94 Stipek, 1997, The effect of quinolinate on rat brain lipid peroxidation is dependent on iron, Neurochem. Int., 30, 233, 10.1016/S0197-0186(97)90002-4 Stone, 2002, The pharmacological manipulation of glutamate receptors and neuroprotection, Eur. J. Pharmacol., 447, 285, 10.1016/S0014-2999(02)01851-4 Stone, 1988, NMDA receptors and ligands in the vertebrate CNS, Prog. Neurobiol., 30, 333, 10.1016/0301-0082(88)90027-5 Stone, 2002, Endogenous kynurenines as targets for drug discovery and development, Nat. Rev. Drug Discov., 1, 609, 10.1038/nrd870 Stone, 2012, Involvement of kynurenines in Huntington's disease and stroke-induced brain damage, J. Neural Transm., 119, 261, 10.1007/s00702-011-0676-8 Stone, 1993, Subtypes of NMDA receptors, Gen. Pharmacol., 24, 825, 10.1016/0306-3623(93)90155-Q Stone, 2000, Development and therapeutic potential of kynurenic acid and kynurenine derivatives for neuroprotection, Trends Pharmacol. Sci., 21, 149, 10.1016/S0165-6147(00)01451-6 Sundaram, 2014, Quinolinic acid toxicity on oligodendroglial cells: relevance for multiple sclerosis and therapeutic strategies, J. Neuroinflammation, 11, 204, 10.1186/s12974-014-0204-5 Tas, 2007, Noncanonical NF-kappaB signaling in dendritic cells is required for indoleamine 2,3-dioxygenase (IDO) induction and immune regulation, Blood, 110, 1540, 10.1182/blood-2006-11-056010 Tavares, 2000, Quinolinic acid inhibits glutamate uptake into synaptic vesicles from rat brain, Neuroreport, 11, 249, 10.1097/00001756-200002070-00005 Tavares, 2002, Quinolinic acid stimulates synaptosomal glutamate release and inhibits glutamate uptake into astrocytes, Neurochem. Int., 40, 621, 10.1016/S0197-0186(01)00133-4 Testa, 1985, The iron-chelating agent picolinic acid enhances transferrin receptors expression in human erythroleukaemic cell lines, Br. J. Haematol., 60, 491, 10.1111/j.1365-2141.1985.tb07446.x Ting, 2007, The involvement of astrocytes and kynurenine pathway in Alzheimer's disease, Neurotox. Res., 12, 247, 10.1007/BF03033908 Ting, 2009, Effect of quinolinic acid on human astrocytes morphology and functions: implications in Alzheimer's disease, J. Neuroinflamm., 6, 36, 10.1186/1742-2094-6-36 Torok, 2015, The genetic link between parkinson's disease and the kynurenine pathway is still missing, Parkinsons Dis., 2015, 474135 Tufi, 2014, Enhancing nucleotide metabolism protects against mitochondrial dysfunction and neurodegeneration in a PINK1 model of Parkinson's disease, Nat. Cell Biol., 16, 157, 10.1038/ncb2901 Urenjak, 2000, Kynurenine 3-hydroxylase inhibition in rats: effects on extracellular kynurenic acid concentration and N-methyl-D-aspartate-induced depolarisation in the striatum, J. Neurochem., 75, 2427, 10.1046/j.1471-4159.2000.0752427.x Valero, 2014, Mitochondrial biogenesis: pharmacological approaches, Curr. Pharm. Des., 20, 5507, 10.2174/138161282035140911142118 Van der Perren, 2015, FK506 reduces neuroinflammation and dopaminergic neurodegeneration in an alpha-synuclein-based rat model for Parkinson's disease, Neurobiol. Aging, 36, 1559, 10.1016/j.neurobiolaging.2015.01.014 Vandresen-Filho, 2015, Cerebral cortex, hippocampus, striatum and cerebellum show differential susceptibility to quinolinic acid-induced oxidative stress, Neurol. Sci., 36, 1449, 10.1007/s10072-015-2180-7 Vazey, 2006, Transplanted adult neural progenitor cells survive: differentiate and reduce motor function impairment in a rodent model of Huntington's disease, Exp. Neurol., 199, 384, 10.1016/j.expneurol.2006.01.034 Vecsei, 2013, Kynurenines in the CNS: recent advances and new questions, Nat. Rev. Drug Discov., 12, 64, 10.1038/nrd3793 Venero, 1995, Intrastriatal quinolinic acid injections protect against 6-hydroxydopamine-induced lesions of the dopaminergic nigrostriatal system, Brain Res., 672, 153, 10.1016/0006-8993(94)01368-R Vicente Miranda, 2010, The sour side of neurodegenerative disorders: the effects of protein glycation, J. Pathol., 221, 13, 10.1002/path.2682 Vila, 1997, Consequences of nigrostriatal denervation on the functioning of the basal ganglia in human and non-human primates: an in situ hybridization study of cytochrome oxidase subunit I mRNA, J. Neurosci., 15, 765, 10.1523/JNEUROSCI.17-02-00765.1997 Walker, 2013, NMDA receptor blockade by ketamine abrogates lipopolysaccharide-Induced depressive-Like behavior in C57BL/6J mice, Neuropsychopharmacology, 38, 1609, 10.1038/npp.2013.71 Wang, 2012, Kinases and kinase signaling pathways: potential therapeutic targets in Parkinson's disease, Prog. Neurobiol., 98, 207, 10.1016/j.pneurobio.2012.06.003 Widner, 2002, Neopterin production, tryptophan degradation, and mental depression–what is the link?, Brain Behav. Immun., 16, 590, 10.1016/S0889-1591(02)00006-5 Widner, 2002, Increased neopterin production and tryptophan degradation in advanced Parkinson's disease, J. Neural Transm., 109, 181, 10.1007/s007020200014 Winklhofer, 2010, Mitochondrial dysfunction in Parkinson's disease, Biochim. Biophys. Acta, 1802, 29, 10.1016/j.bbadis.2009.08.013 Wonodi, 2011, Downregulated kynurenine 3-monooxygenase gene expression and enzyme activity in schizophrenia and genetic association with schizophrenia endophenotypes, Arch. Gen. Psychiatry, 68, 665, 10.1001/archgenpsychiatry.2011.71 Wu, 2000, Systemic administration of 4-chlorokynurenine prevents quinolinate neurotoxicity in the rat hippocampus, Eur. J. Pharmacol., 390, 267, 10.1016/S0014-2999(00)00024-8 Yeh, 2012, Acute onset of parkinsonism with reversible course after H1N1 vaccination: insight from a young lady, J. Neuropsychiatr. Clin. Neurosci., 24, E34, 10.1176/appi.neuropsych.11110324 Zadori, 2011, Time-course of kynurenic acid concentration in mouse serum following the administration of a novel kynurenic acid analog, J. Pharm. Biomed. Anal., 55, 540, 10.1016/j.jpba.2011.02.014 Zadori, 2012, Kynurenines in Parkinson's disease: therapeutic perspectives, J. Neural Transm., 119, 275, 10.1007/s00702-011-0697-3 Zaitone, 2012, Acetyl-L-carnitine and alpha-lipoic acid affect rotenone-induced damage in nigral dopaminergic neurons of rat brain, implication for Parkinson's disease therapy, Pharmacol. Biochem. Behav., 100, 347, 10.1016/j.pbb.2011.09.002 Zecca, 2003, Neuromelanin of the substantia nigra: a neuronal black hole with protective and toxic characteristics, Trends Neurosci., 26, 578, 10.1016/j.tins.2003.08.009 Zhu, 1989, Effect of MK-801 kynurenate, glycine, dextrorphan and 4-acetylpyridine on striatal toxicity of quinolinate, Brain Res., 481, 356, 10.1016/0006-8993(89)90814-7 Zinger, 2011, The involvement of neuroinflammation and kynurenine pathway in Parkinson's disease, Parkinsons Dis., 2011, 716859